Q-omics provides the consensus-scored SPARCL1 profile across patient tissues and cancer cell-line models. SPARCL1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SPARCL1 is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, SPARCL1 RNA expression shows 23,465 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, BLCA, and BRCA as cancer lineages where SPARCL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPARCL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPARCL1 survival associations across molecular data types. SPARCL1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPARCL1 RNA expression–survival associations across cancer types. High SPARCL1 expression shows unfavorable associations in UVM, BLCA and KIRP, but favorable associations in KIRC, LIHC and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SPARCL1 RNA expression.
This table summarizes SPARCL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SPARCL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPARCL1 shows lower tumor expression in BLCA, LUAD, COAD and THCA and higher tumor expression in KIRC and LIHC. The BLCA box plot shows higher SPARCL1 RNA expression in normal versus tumor tissue (log2 FC = −3.938, t-test p < 0.001).
This table shows molecular features associated with SPARCL1 in patient tissues and cancer cell lines. In patient samples, SPARCL1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SPARCL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
